The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 602,887 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 32.55% since February 29, 2016 and is downtrending. It has underperformed by 44.77% the S&P500.
The move comes after 6 months positive chart setup for the $865.77M company. It was reported on Oct, 3 by Barchart.com. We have $17.84 PT which if reached, will make NASDAQ:INSY worth $380.94M more.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.19 million for 51.63 P/E if the $0.06 EPS becomes a reality. After $0.06 actual earnings per share reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 8 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Tuesday, April 12. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Outperform” rating given on Thursday, September 22 by RBC Capital Markets. The firm earned “Hold” rating on Tuesday, August 4 by Oppenheimer. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Wednesday, February 24. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Buy” rating by Jefferies on Thursday, August 4. The rating was downgraded by Zacks on Friday, August 14 to “Buy”. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The stock has “Buy” rating given by Janney Capital on Thursday, April 14.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio fall, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Adage Capital Prtn Limited Liability owns 275,000 shares or 0.01% of their US portfolio. Citigroup Incorporated, a New York-based fund reported 18,511 shares. Vanguard Group has 2.38M shares for 0% of their US portfolio. Macguire Cheswick & Tuttle Investment Counsel Lc reported 10,265 shares or 0.03% of all its holdings. Ladenburg Thalmann Fincl Ser Inc has 0% invested in the company for 2,435 shares. Raging Cap Mngmt Llc last reported 0.15% of its portfolio in the stock. Northern Trust Corp has 0% invested in the company for 298,672 shares. 12 West Cap Management L P accumulated 1.3% or 623,791 shares. Parametric Port Associates owns 15,197 shares or 0% of their US portfolio. Bridgeway Management has 13,000 shares for 0% of their US portfolio. Orbimed Advsr Ltd Com has invested 0.63% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Wealthtrust last reported 0% of its portfolio in the stock. Dekabank Deutsche Girozentrale owns 38,100 shares or 0.01% of their US portfolio. Cypress Funds Limited Liability Corp reported 135,584 shares or 0.41% of all its holdings. Blackrock Fund, a California-based fund reported 1.48M shares.
Insider Transactions: Since May 11, 2016, the stock had 2 insider buys, and 4 sales for $170,592 net activity. Another trade for 5,700 shares valued at $105,853 was made by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Friday, August 12. Shares for $270,300 were sold by STANLEY THEODORE H. $110,752 worth of Insys Therapeutics Inc (NASDAQ:INSY) shares were sold by BRENNAN DANIEL. $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by FOURTEAU PATRICK on Thursday, August 11.
More notable recent Insys Therapeutics Inc (NASDAQ:INSY) news were published by: Fool.com which released: “Here’s Why Insys Therapeutics Inc. Fell 14.3% in April” on May 10, 2016, also Globenewswire.com with their article: “Insys Therapeutics Announces CEO Succession Plan” published on September 21, 2016, Businessinsider.com published: “A pharmaceutical company is fighting marijuana legalization because it would …” on September 13, 2016. More interesting news about Insys Therapeutics Inc (NASDAQ:INSY) were released by: Prnewswire.com and their article: “Purcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for …” published on August 30, 2016 as well as Finance.Yahoo.com‘s news article titled: “Insys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference” with publication date: August 18, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.